08:33 AM EDT, 05/14/2025 (MT Newswires) -- Sernova Biotherapeutics ( SEOVF ) on Wednesday said interim data from its ongoing Phase 1/2 clinical trial in patients with type 1 diabetes (T1D) show a majority of the enrolled patients achieving insulin independence and improved blood sugar control.

The clinical trial involved transplanting Sernova's cell pouch with human donor cells or stem-cell derived islet-like clusters to create bio-hybrid organs to treat T1D.

Eight of the 12 patients have achieved insulin independence and the study is on track to meet its primary and secondary endpoints. Cohort C is expected to initiate in the second half of this year, the company confirmed.